Search details
1.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Future Oncol
; 20(8): 423-436, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37387213
2.
Estimands for overall survival in clinical trials with treatment switching in oncology.
Pharm Stat
; 21(1): 150-162, 2022 01.
Article
in English
| MEDLINE | ID: mdl-34605168
3.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood
; 131(14): 1522-1531, 2018 04 05.
Article
in English
| MEDLINE | ID: mdl-29358182
4.
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Cancer
; 119(24): 4290-8, 2013 Dec 15.
Article
in English
| MEDLINE | ID: mdl-24122767
5.
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
N Engl J Med
; 355(10): 983-91, 2006 Sep 07.
Article
in English
| MEDLINE | ID: mdl-16957145
6.
Importance of contact surface between electrodes and treated tissue in electrochemotherapy.
Technol Cancer Res Treat
; 7(5): 393-400, 2008 Oct.
Article
in English
| MEDLINE | ID: mdl-18783290
7.
Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program.
Clin Cancer Res
; 13(13): 3892-8, 2007 Jul 01.
Article
in English
| MEDLINE | ID: mdl-17606722
8.
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Lung Cancer
; 104: 119-125, 2017 02.
Article
in English
| MEDLINE | ID: mdl-28212993
9.
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
J Clin Oncol
; 35(36): 4027-4034, 2017 Dec 20.
Article
in English
| MEDLINE | ID: mdl-28968167
10.
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers.
Sci Transl Med
; 9(415)2017 Nov 08.
Article
in English
| MEDLINE | ID: mdl-29118262
11.
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Clin Cancer Res
; 23(18): 5489-5501, 2017 Sep 15.
Article
in English
| MEDLINE | ID: mdl-28559461
12.
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
J Thorac Oncol
; 8(3): 329-37, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23370314
13.
Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice.
J Thorac Oncol
; 4(12): 1504-10, 2009 Dec.
Article
in English
| MEDLINE | ID: mdl-19745763
14.
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
J Clin Oncol
; 27(15): 2429-35, 2009 May 20.
Article
in English
| MEDLINE | ID: mdl-19364971
15.
Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
J Clin Oncol
; 25(19): 2735-40, 2007 Jul 01.
Article
in English
| MEDLINE | ID: mdl-17602078
Results
1 -
15
de 15
1
Next >
>>